Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ766141B2 - Isoxazoline parasiticide formulations and methods for treating blepharitis - Google Patents
[go: Go Back, main page]

NZ766141B2 - Isoxazoline parasiticide formulations and methods for treating blepharitis - Google Patents

Isoxazoline parasiticide formulations and methods for treating blepharitis

Info

Publication number
NZ766141B2
NZ766141B2 NZ766141A NZ76614118A NZ766141B2 NZ 766141 B2 NZ766141 B2 NZ 766141B2 NZ 766141 A NZ766141 A NZ 766141A NZ 76614118 A NZ76614118 A NZ 76614118A NZ 766141 B2 NZ766141 B2 NZ 766141B2
Authority
NZ
New Zealand
Prior art keywords
methods
isoxazoline parasiticide
patient
blepharitis
disclosed
Prior art date
Application number
NZ766141A
Other versions
NZ766141A (en
Inventor
Douglas Michael Ackermann
Bobak Robert Azamian
Shawn D Hickok
Joseph G Vehige
Original Assignee
Tarsus Pharmaceuticals Inc
Filing date
Publication date
Application filed by Tarsus Pharmaceuticals Inc filed Critical Tarsus Pharmaceuticals Inc
Priority claimed from PCT/US2018/065849 external-priority patent/WO2019118928A1/en
Publication of NZ766141A publication Critical patent/NZ766141A/en
Publication of NZ766141B2 publication Critical patent/NZ766141B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Abstract

Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed.

Claims (1)

1. CLAIM This application claims the benefit under 35 U.S.C. ยง 119(e) as a nonprovisional application of each of U.S. Prov. App. Nos.
NZ766141A 2018-12-14 Isoxazoline parasiticide formulations and methods for treating blepharitis NZ766141B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762599213P 2017-12-15 2017-12-15
US201862615855P 2018-01-10 2018-01-10
US201862626612P 2018-02-05 2018-02-05
US201862689787P 2018-06-25 2018-06-25
US201862746498P 2018-10-16 2018-10-16
PCT/US2018/065849 WO2019118928A1 (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methods for treating blepharitis

Publications (2)

Publication Number Publication Date
NZ766141A NZ766141A (en) 2024-01-26
NZ766141B2 true NZ766141B2 (en) 2024-04-30

Family

ID=

Similar Documents

Publication Publication Date Title
EP4397375A3 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
MX2021016055A (en) FORMULATIONS AND METHODS OF ISOXAZOLINE PARASITICIDES FOR THE TREATMENT OF BLEPHARITIS.
WO2023114943A3 (en) Lipids for use in lipid nanoparticle formulations
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
WO2020083971A3 (en) New anthelmintic compounds
MX2010003774A (en) Aqueous ophthalmic formulations.
WO2012136969A3 (en) Ophthalmic treatments
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
WO2007106381A3 (en) Ophthalmic compositions comprising povidone-iodine
DE602006006308D1 (en) SUSPENSION FORMULATIONS USING AN ACTIVE AGENT, A POLOXAMER OR MEROXAPOL TENSID AND A GLYCOL AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF EYE DISEASES
AU2017261303A1 (en) Ophthalmic compositions
US20190008832A1 (en) Compositions for the treatment of presbyopia
WO2005087195A3 (en) Novel compositions for topical delivery
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
MX2009013062A (en) 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same.
MX2021015781A (en) Lipid-based formulation for topical ophthalmic use, containing blueberry extract as the main component to make more efficient penetration and bioavailability of its bioactive in intraocular white tissues in humans.
ZA202309969B (en) Laquinimod formulation for ocular use
WO2022020114A3 (en) Methods for the prevention and treatment of hearing loss
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
AR055591A1 (en) A SKIN PROTECTIVE TOPIC COMPOSITION AND ITS USE
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
WO2017152129A3 (en) Treatment of glaucoma and/or retinal diseases and formulations useful therefore
MX2021009777A (en) Injectable phenol formulations and methods of their use.
MX2024003015A (en) NEW QUINOLINE DERIVATIVES.